FrancophonIA/ELRC3.0 huggingface dataset:
English: 2 x 1 orodispersible tablet: EU/1/09/551/019 4 x 1 orodispersible tablet: EU/1/09/551/020 8 x 1 orodispersible tablet: EU/1/09/551/021 12 x 1 orodispersible tablet: EU/1/09/551/022 24 x 1 orodispersible tablet: EU/1/09/551/028
Estonian: 2 x 1 suus dispergeeruv tablett: EU/1/09/551/019 4 x 1 suus dispergeeruv tablett: EU/1/09/551/020 8 x 1 suus dispergeeruv tablett: EU/1/09/551/021 12 x 1 suus dispergeeruv tablett: EU/1/09/551/022 24 x 1 suus dispergeeruv tablett: EU/1/09/551/028
English: 1 orodispersible tablet: EU/1/09/551/013 2 x 1 orodispersible tablet: EU/1/09/551/014 4 x 1 orodispersible tablet: EU/1/09/551/015 8 x 1 orodispersible tablet: EU/1/09/551/016 12 x 1 orodispersible tablet: EU/1/09/551/017
Estonian: 1 suus dispergeeruv tablett: EU/1/09/551/013 2 x 1 suus dispergeeruv tablett: EU/1/09/551/014 4 x 1 suus dispergeeruv tablett: EU/1/09/551/015 8 x 1 suus dispergeeruv tablett: EU/1/09/551/016 12 x 1 suus dispergeeruv tablett: EU/1/09/551/017
English: Vizarsin 25 mg orodispersible tablets Sildenafil
Estonian: Vizarsin 25 mg suus dispergeeruvad tabletid Sildenafiil
English: Vizarsin 100 mg orodispersible tablets Sildenafil
Estonian: Vizarsin 100 mg suus dispergeeruvad tabletid Sildenafiil
English: Epistaxis, Sinus congestion
Estonian: Peapööritus, tinnitus Kurtus
English: 2 x 1 orodispersible tablet: EU/1/09/551/014 4 x 1 orodispersible tablet: EU/1/09/551/015 8 x 1 orodispersible tablet: EU/1/09/551/016 12 x 1 orodispersible tablet: EU/1/09/551/017
Estonian: 2 x 1 suus dispergeeruv tablett: EU/1/09/551/014 4 x 1 suus dispergeeruv tablett: EU/1/09/551/015 8 x 1 suus dispergeeruv tablett: EU/1/09/551/016 12 x 1 suus dispergeeruv tablett: EU/1/09/551/017
English: 1 film-coated tablet: EU/1/09/551/009
Estonian: 1 õhukese polümeerikattega tablett: EU/1/09/551/009
English: Vizarsin 100 mg film-coated tablets 1 film-coated tablet: EU/1/09/551/009
Estonian: Vizarsin 100 mg õhukese polümeerikattega tabletid 1 õhukese polümeerikattega tablett: EU/1/09/551/009
English: Vizarsin 100 mg film-coated tablets are available in boxes of 1 film-coated tablet in blisters and also in boxes of 4 x 1, 8 x 1 or 12 x 1 film-coated tablet in a perforated unit dose blisters.
Estonian: Vizarsin 100 mg õhukese polümeerikattega tabletid on saadaval 1 kaupa blistrites ja karpides ning 4 x 1, 8 x 1 või 12 x 1 kaupa perforeeritud üksikannuselistes blisterpakendites ja karpides.
English: I, /* I
Estonian: I'\V
English: Vizarsin 50 mg orodispersible tablets Sildenafil
Estonian: Vizarsin 50 mg suus dispergeeruvad tabletid Sildenafiil
English: 1 film-coated tablet: EU/1/09/551/005
Estonian: 1 õhukese polümeerikattega tablett: EU/1/09/551/005
English: Vizarsin 25 mg film-coated tablets are available in boxes of 1 film-coated tablet in blisters and also in boxes of 4 x 1, 8 x 1 or 12 x 1 film-coated tablet in a perforated unit dose blisters.
Estonian: Vizarsin 25 mg õhukese polümeerikattega tabletid on saadaval 1 kaupa blistrites ja karpides ning 4 x 1, 8 x 1 või 12 x 1 kaupa perforeeritud üksikannuselistes blisterpakendites ja karpides.
English: Vizarsin 50 mg film-coated tablets are available in boxes of 1 film-coated tablet in blisters and also in boxes of 4 x 1, 8 x 1 or 12 x 1 film-coated tablet in a perforated unit dose blisters.
Estonian: Vizarsin 50 mg õhukese polümeerikattega tabletid on saadaval 1 kaupa blistrites ja karpides ning 4 x 1, 8 x 1 või 12 x 1 kaupa perforeeritud üksikannuselistes blisterpakendites ja karpides.
English: Blister (perforated unit dose blister, PVC-foil/Alu-foil): 4 x 1, 8 x 1 or 12 x 1 film-coated tablet, in a carton.
Estonian: PVC/Al-foolium perforeeritud üksiskannuseline blister: 4 x 1, 8 x 1 või 12 x 1 õhukese polümeerikattega tabletti karbis.
English: Vizarsin 50 mg film-coated tablets 1 film-coated tablet: EU/1/09/551/005
Estonian: Vizarsin 50 mg õhukese polümeerikattega tabletid 1 õhukese polümeerikattega tablett: EU/1/09/551/005
English: Vizarsin 25 mg film-coated tablets 1 film-coated tablet: EU/1/09/551/001
Estonian: Vizarsin 25 mg õhukese polümeerikattega tabletid 1 õhukese polümeerikattega tablett: EU/1/09/551/001
English: Vizarsin 100 mg film-coated tablets Sildenafil
Estonian: Vizarsin 100 mg õhukese polümeerikattega tabletid Sildenafiil
English: Uncommon ( 1/1000 and
Estonian: Harv (≥ 1/10 000 ja häired kinnisus
English: - If you are using any of the medicines known as nitric oxide donors such as amyl nitrite
Estonian: Seetõttu on sildenafiil vastunäidustatud patsientidele, kes kasutavad lämmastikoksiidi doonoreid (näiteks amüülnitrit) või mis tahes vormis nitraate.
English: Transient ischaemic attack, Seizure Seizure recurrence Syncope
Estonian: Unisus, hüpesteesia Insult, transitoorne isheemiline atakk, krambid,* korduvad krambid,
English: Iskedyl Fort tablets
Estonian: Iskedyl Fort tabletid
English: Czech Republic TEVA Czech Industries s.r.o.
Estonian: Tšehhi Vabariik TEVA Czech Industries s.r.o.
English: PRT Lagoas Park, Edifício 11 2740-270 Porto Salvo Portugal
Estonian: PRT Lagoas Park, Edifício 11 2740-270 Porto Salvo Portugal kõvakapslid
English: ERGODAVUR GOTAS 1 mg (monodose suchet)
Estonian: ERGODAVUR GOTAS 1 mg (üheannuseline kotike)
English: G. KORONIS DILOU 9, PERISTERI, ATTIKIS, 12134 Greece
Estonian: G. KORONIS DILOU 9, PERISTERI, ATTIKIS, 12134
English: 2.5 mg (1:1:1) prolonged-release capsule, soft
Estonian: 2,5 mg (1:1:1) toimeainet prolongeeritult vabastav pehmekapsel
English: 0.10 g / 0.80 g oral solution
Estonian: 0,10 g/0,80 g suukaudne lahus
English: ISKEDYL, solution injectable en ampoule solution for injection IV/IM
Estonian: ISKEDYL, solution injectable en ampoule süstelahus
English: 3mg/cap capsules, soft
Estonian: 3 mg/kapsel pehmekapslid
English: 6MG/SINGLE DOSE
Estonian: 6 mg/annuses Üksikannuse suukaudse lahuse pulber
English: This summary was last updated in November 2016.
Estonian: Kokkuvõtte viimane uuendus: november 2016.
English: This will help protect the pigs against the infection and reduce the risk of disease.
Estonian: See aitab kaitsta sigu infektsiooni eest ja vähendab haiguse tekkimise riski.
English: E. coli O8:K87 / O141:K94 vaccine (live)
Estonian: E. coli O8:K87 / O141:K94 vaktsiin (elusvaktsiin)
English: This is more likely to occur at weaning time when the piglet no longer receives protecting antibodies through the sow's milk.
Estonian: See võib sagedamini ilmneda võõrutamise ajal, kui põrsas ei saa enam emise piimast kaitsvaid antikehi.
English: The strains of bacteria in the vaccine have these proteins but do not produce the toxins that cause the disease.
Estonian: Vaktsiini bakteritüvedel on need valgud olemas, kuid need ei tekita haigust põhjustavaid toksiine.
English: The full EPAR for Coliprotec F4/F18 can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst vaktsiini Coliprotec F4/F18 kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The effectiveness of the vaccine was studied in four laboratory studies in pigs that looked chiefly at the incidence, severity and duration of diarrhoea as well as the presence of disease-causing E. coli in the animals' excrement.
Estonian: Vaktsiini efektiivsust sigadel uuriti neljas laboriuuringus, milles keskenduti peamiselt kõhulahtisuse esinemusele, raskusastmele ja kestusele ning haigust põhjustava E. coli esinemusele loomade väljaheites.
English: Although E. coli bacteria are naturally found in the gut, some strains (known as enterotoxigenic strains) produce toxins that cause diarrhoea and can result in dehydration, weight loss and occasionally death of the animal.
Estonian: Kuigi E. coli bakterid esinevad sooles looduslikult, tekitavad mõned tüved (enterotoksigeensed tüved) toksiine, mis põhjustavad kõhulahtisust ning millega võib kaasneda dehüdratsioon, kaalulangus ja mõnikord looma surm.
English: Two studies showed the vaccine starts to be effective 7 days after vaccination and two studies showed protection lasts for 21 days after vaccination.
Estonian: Kaks uuringut tõendasid, et vaktsiin hakkab toimima 7 päeva pärast vaktsineerimist ja kaitse kestab vaktsineerimise järel 21 päeva.
English: The vaccine starts to be effective 7 days after vaccination and protection lasts for 21 days after vaccination.
Estonian: Vaktsiin hakkab toimima 7 päeva pärast vaktsineerimist ja kaitse kestab vaktsineerimise järel 21 päeva.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Coliprotec F4/F18's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et vaktsiini Coliprotec F4/F18 kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas vaktsiini kasutamise Euroopa Liidus heaks kiita.
English: Two studies used the F4 strain while the other two used the F18 strain.
Estonian: Kahes uuringus kasutati tüve F4 ja kahes teises tüve F18.
English: Coliprotec F4/F18 contains two strains of live E. coli bacteria (O8:K87 and O141:K94) which do not produce toxins that cause disease.
Estonian: Coliprotec F4/F18 sisaldab kaht E. coli elusbakteri tüve (O8:K87 ja O141:K94), mis ei tekita haigust põhjustavaid toksiine.
English: Pigs aged 17 - 18 days were vaccinated with Coliprotec F4/F18 and then artificially infected with E. coli strains.
Estonian: 17-18 päeva vanuseid sigu vaktsineeriti vaktsiiniga Coliprotec F4/F18 ja seejärel nakatati nad kunstlikult E. coli tüvedega.
English: The types of E. coli associated with post-weaning diarrhoea often produce proteins called F4 and F18 on their outer coat that allows them to attach to the cells of the gut.
Estonian: E. coli tüübid, mida seostatakse võõrutusjärgse kõhulahtisusega, tekitavad oma väliskestal sageli valke F4 ja F18 ning see võimaldab neil kinnituda soolerakkudele.
English: The vaccine reduced the number of pigs with moderate to severe diarrhoea compared to non-vaccinated pigs.
Estonian: Võrreldes vaktsineerimata sigadega, vähendas vaktsiin sigade arvu, kellel esines mõõdukas kuni raske kõhulahtisus.
English: In case of accidental ingestion, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
Estonian: Juhuslikul allaneelamisel tuleb pöörduda kohe arsti poole ja näidata talle pakendi infolehte või etiketti.
English: In case of spillage onto skin, the affected area should be rinsed with water and medical advice should be sought immediately and the package leaflet or label shown to the doctor.
Estonian: Nahale sattumisel tuleb seda kohta pesta veega, pöörduda kohe arsti poole ja näidata talle pakendi infolehte või etiketti.
English: The withdrawal period for meat from pigs treated with Coliprotec F4/F18 is ‘zero' days, which means there is no mandatory waiting time.
Estonian: Vaktsiiniga Coliprotec F4/F18 ravitud sigade liha keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: For practical information about using Coliprotec F4/F18, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Estonian: Kui loomaomanikud või -pidajad vajavad vaktsiini Coliprotec F4/F18 kasutamise praktilisi nõuandeid, peavad nad lugema pakendi infolehte või pöörduma oma veterinaararsti või apteekri poole.
English: Coliprotec F4/F18 is a vaccine used to protect pigs from 18 days of age against post-weaning diarrhoea caused by E. coli.
Estonian: Coliprotec F4/F18 on vaktsiin, mida kasutatakse vähemalt 18päevaste sigade kaitsmiseks bakteri E. coli põhjustatud võõrutusjärgse kõhulahtisuse eest.
English: What is Coliprotec F4/F18 and what is it used for?
Estonian: Mis on Coliprotec F4/F18 ja milleks seda kasutatakse?
English: When Coliprotec F4/F18 is given to pigs, the animals' immune system recognises the bacteria as ‘foreign' and makes antibodies against them.
Estonian: Kui sigadele manustatakse vaktsiini Coliprotec F4/F18, peab loomade immuunsüsteem vaktsiinis sisalduvaid baktereid võõraks ja tekitab nende vastu antikehi.
English: Coliprotec F4/F18 is given by mouth to pigs as a single dose either as a drench or by addition to the drinking water.
Estonian: Vaktsiini Coliprotec F4/F18 manustatakse sigadele suukaudselt ühekordse annusena kas jootmisvahendi kaudu või lisatuna joogiveele.
English: In the future, if the animals are exposed to disease-causing bacteria with the F4 or F18 proteins, the immune system will be able to respond more quickly.
Estonian: Kui loomad puutuvad hiljem haigust põhjustavate F4 ja F18 valkudega bakteritega uuesti kokku, tekivad antikehad kiiremini.
English: Coliprotec F4/F18 is available as a lyophilisate (a freeze-dried pellet) which is made up into a suspension with water to be given by mouth.
Estonian: Vaktsiini Coliprotec F4/F18 turustatakse lüofilisaadina (külmkuivatatud graanulitena), millest valmistatakse vett lisades suukaudne suspensioon.
English: This is a summary of the European public assessment report (EPAR) for Coliprotec F4/F18.
Estonian: See on vaktsiini Coliprotec F4/F18 Euroopa avaliku hindamisaruande kokkuvõte.
English: It is not intended to provide practical advice on how to use Coliprotec F4/F18.
Estonian: Hindamisaruandes ei anta vaktsiini Coliprotec F4/F18 kasutamise praktilisi nõuandeid.
English: Why is Coliprotec F4/F18 approved?
Estonian: Miks Coliprotec F4/F18 heaks kiideti?
English: Coliprotec F4/F18 is a vaccine.
Estonian: Coliprotec F4/F18 on vaktsiin.
English: The European Commission granted a marketing authorisation valid throughout the EU for Coliprotec F4/F18 on 9 January 2017.
Estonian: Euroopa Komisjon andis vaktsiinile Coliprotec F4/F18 müügiloa, mis kehtib kogu Euroopa Liidus,
English: What are the risks associated with Coliprotec F4/F18?
Estonian: Mis riskid vaktsiiniga Coliprotec F4/F18 kaasnevad?
English: How does Coliprotec F4/F18 work?
Estonian: Kuidas Coliprotec F4/F18 toimib?
English: Other information about Coliprotec F4/F18?
Estonian: Muu teave Coliprotec F4/F18 kohta
English: There are currently no known side effects associated with Coliprotec F4/F18.
Estonian: Vaktsiiniga Coliprotec F4/F18 kaasnevaid kõrvalnähtusid ei ole praegu teada.
English: How is Coliprotec F4/F18 used?
Estonian: Kuidas vaktsiini Coliprotec F4/F18 kasutatakse?
English: What benefits of Coliprotec F4/F18 have been shown in studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Coliprotec F4/F18 kasulikkus?
English: Vosevi must not be used together with certain medicines such as:
Estonian: Vosevit ei tohi kasutada koos teatud ravimitega, näiteks järgmistega:
English: What measures are being taken to ensure the safe and effective use of Vosevi?
Estonian: Mis meetmed võetakse, et tagada Vosevi ohutu ja efektiivne kasutamine?
English: The recommended dose is one tablet taken once a day with food for 8 or 12 weeks.
Estonian: Soovitatav annus on üks tablett üks kord ööpäevas koos toiduga 8 või 12 nädala jooksul.
English: The full EPAR for Vosevi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Vosevi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Vosevi
Estonian: Muu teave Vosevi kohta
English: What is Vosevi and what is it used for?
Estonian: Mis on Vosevi ja milleks seda kasutatakse?
English: The European Medicines Agency therefore decided that Vosevi's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Vosevi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Why is Vosevi approved?
Estonian: Miks Vosevi heaks kiideti?
English: Sofosbuvir/velpatasvir has been authorised in the EU as Epclusa since July 2016.
Estonian: Sofosbuviiril/velpatasviiril on Euroopa Liidus müügiluba ravimina Epclusa alates 2016. aasta juulist.
English: What are the risks associated with Vosevi?
Estonian: Mis riskid Voseviga kaasnevad?
English: Vosevi sofosbuvir / velpatasvir / voxilaprevir
Estonian: Vosevi sofosbuviir/velpatasviir/voksilapreviir
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vosevi have also been included in the summary of product characteristics and the package leaflet.
Estonian: Vosevi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: It is not intended to provide practical advice on how to use Vosevi.
Estonian: Hindamisaruandes ei anta Vosevi kasutamise praktilisi nõuandeid.
English: Vosevi is available as tablets containing 400 mg sofosbuvir, 100 mg velpatasvir and 100 mg voxilaprevir.
Estonian: Vosevit turustatakse tablettidena, mis sisaldavad 400 mg sofosbuviiri, 100 mg velpatasviiri ja 100 mg voksilapreviiri.
English: The most common side effects with Vosevi (which may affect more than 1 in 10 people) are headache, nausea (feeling sick) and diarrhoea.
Estonian: Vosevi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on peavalu, iiveldus ja kõhulahtisus.
English: This is a summary of the European public assessment report (EPAR) for Vosevi.
Estonian: See on ravimi Vosevi Euroopa avaliku hindamisaruande kokkuvõte.
English: This study is being carried out in light of data suggesting that patients treated with medicines belonging to the same class as Vosevi who have had liver cancer could be at risk of their cancer returning early.
Estonian: Uuring tehakse andmete põhjal, et patsientidel, keda on ravitud Voseviga samasse klassi kuuluvate ravimitega ja kellel on varem olnud maksavähk, võib olla vähi varajase taastumise risk.
English: Regarding safety, Vosevi was well tolerated with no major safety concern emerging.
Estonian: Ohutuse kohta märgiti, et patsiendid talusid Vosevit hästi ning olulisi ohutusprobleeme ei täheldatud.
English: • carbamazepine, phenobarbital, phenytoin (medicines for epilepsy);
Estonian: • karbamasepiin, fenobarbitaal, fenütoiin (epilepsiaravimid);
English: For the full list of side effects and restrictions with Vosevi, see the package leaflet.
Estonian: Vosevi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: By blocking these proteins, Vosevi stops the hepatitis C virus from multiplying and infecting new cells.
Estonian: Neid valke blokeerides peatab Vosevi C-hepatiidi viiruse paljunemise ja uute rakkude nakatumise.
English: The company that markets Vosevi will carry out a study in patients who previously have had liver cancer to evaluate the risk of liver cancer returning after treatment with direct-acting antivirals.
Estonian: Vosevi turustaja teeb nende patsientide uuringu, kellel on varem olnud maksavähk, et hinnata maksavähi taastumise riski pärast ravi otsese toimega viirusvastaste ravimitega.
English: For practical information about using Vosevi, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Vosevi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Sofosbuvir blocks the action of an enzyme (a type of protein) called ‘NS5B RNA-dependent RNA polymerase', velpatasvir targets a protein called ‘NS5A', while voxilaprevir blocks an enzyme called NS3/4A protease.
Estonian: Sofosbuviir blokeerib ensüümi (teatud valk) NS5B, RNAsõltuva viiruse paljunemiseks vajaliku RNA polümeraasi toime, velpatasviir blokeerib valgu NS5A toime ja voksilapreviir ensüümi NS3/4A proteaasi toime.
English: How is Vosevi used?
Estonian: Kuidas Vosevit kasutatakse?
English: The duration of treatment depends on whether patients have liver cirrhosis (scarring of the liver) or have received treatment with other direct-acting antivirals.
Estonian: Ravi kestus sõltub sellest, kas patsiendil on maksatsirroos (maksa sidekoestumine) või kas teda on ravitud muude otsese viirusvastase toimega ravimitega.
English: Additionally, Vosevi was shown to be very effective at eliminating the hepatitis C virus in patients in whom previous treatment with a NS5A inhibitor failed.
Estonian: Peale selle osutus Vosevi äärmiselt efektiivseks C-hepatiidi viiruse hävitamisel patsientidel, kellel varasem ravi NS5A inhibiitoriga ei olnud õnnestunud.
English: The active substances in Vosevi (sofosbuvir, velpatasvir and voxilaprevir) block three proteins essential for the hepatitis C virus to multiply.
Estonian: Vosevi toimeained (sofosbuviir, velpatasviir ja voksilapreviir) blokeerivad C-hepatiidi viiruse paljunemiseks vajaliku kolme valgu toime.
English: For more information about treatment with Vosevi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Voseviga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Vosevi can only be obtained with a prescription, and treatment should be started and monitored by a doctor experienced in the management of patients with hepatitis C virus infection.
Estonian: Vosevi on retseptiravim ning ravi sellega peab alustama ja jälgima C-hepatiidi viiruse infektsiooniga patsientide ravis kogenud arst.
English: In two further studies between 95 and 96% of Vosevi patients tested negative for the virus, compared with 96 to 98% of patients taking sofosbuvir/velpatasvir.
Estonian: Kahes ülejäänud uuringus oli viiruse analüüsi negatiivse tulemusega patsiente Vosevi uuringurühmas 95% ja 96% ning sofosbuviiri/velpatasviiri uuringurühmas 96-98%.
English: Vosevi contains the active substances sofosbuvir, velpatasvir and voxilaprevir.
Estonian: Vosevi sisaldab toimeainetena sofosbuviiri, velpatasviiri ja voksilapreviiri.
English: Vosevi is an antiviral medicine used to treat adults with chronic (long-term) hepatitis C, an infectious disease that affects the liver, caused by the hepatitis C virus (HCV).
Estonian: Vosevi on viirusvastane ravim, mida kasutatakse kroonilise (pikaajalise) C-hepatiidi (C-hepatiidi viiruse põhjustatud nakkuslik maksahaigus) raviks täiskasvanutel.
English: What benefits of Vosevi have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Vosevi kasulikkus?
English: How does Vosevi work?
Estonian: Kuidas Vosevi toimib?
English: Over 97% of patients taking Vosevi in a second study tested negative, compared with 90% of patients taking only sofosbuvir/velpatasvir.
Estonian: Teises uuringus oli negatiivse tulemusega patsiente Vosevi uuringurühmas üle 97% ja ainult sofosbuviiri/velpatasviiri kasutanud patsientide seas 90%.
English: • rosuvastatin (medicine for lowering cholesterol in the blood);
Estonian: • rosuvastatiin (vere kolesteroolisisaldust vähendav ravim);
English: Vosevi has been shown in four main studies of 1,459 patients to be effective at clearing all six varieties (genotypes) of the hepatitis C virus, including in patients with liver cirrhosis and those who have previously tried other direct-acting antivirals.
Estonian: Neljas põhiuuringus (1459 patsienti) tõendati Vosevi efektiivsus C-hepatiidi ravis kõigi kuue C-hepatiidi viiruse vormi (genotüübi) korral, sh tsirroosiga patsientidel ja patsientidel, kes olid varem kasutanud muid otsese viirusvastase toimega ravimeid.
English: • rifampicin, rifabutin (antibiotics usually used to treat tuberculosis);
Estonian: • rifampitsiin, rifabutiin (antibiootilised tuberkuloosiravimid);
English: • ethinyl oestradiol-containing products (such as contraceptive medicines);
Estonian: • etinüülöstradiooli sisaldavad ravimid (nt rasestumisvastased ravimid);
English: The clearance rates with Vosevi were typically above 95%.
Estonian: Ravivastusega patsiente oli Vosevi uuringurühmades enamasti üle 95%.
English: • St John's wort (a herbal remedy used for depression and anxiety).
Estonian: • naistepuna (taimne depressiooni ja ärevuse ravim).